AbCellera Biologics Inc.

NasdaqGS:ABCL Voorraadrapport

Marktkapitalisatie: US$803.4m

AbCellera Biologics Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Carl Hansen

Algemeen directeur

US$714.9k

Totale compensatie

Percentage CEO-salaris64.3%
Dienstverband CEO12yrs
Eigendom CEO19.3%
Management gemiddelde ambtstermijn3.3yrs
Gemiddelde ambtstermijn bestuur5.2yrs

Recente managementupdates

Recent updates

AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 07
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates

AbCellera: A Platform To Pipeline Transition

Oct 14

AbCellera: A Waiting Game With High Uncertainty

Aug 23

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

Analyse CEO-vergoeding

Hoe is Carl Hansen's beloning veranderd ten opzichte van AbCellera Biologics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$176m

Jun 30 2024n/an/a

-US$153m

Mar 31 2024n/an/a

-US$147m

Dec 31 2023US$715kUS$460k

-US$146m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$9mUS$450k

US$159m

Sep 30 2022n/an/a

US$248m

Jun 30 2022n/an/a

US$200m

Mar 31 2022n/an/a

US$205m

Dec 31 2021US$9mUS$400k

US$153m

Sep 30 2021n/an/a

US$177m

Jun 30 2021n/an/a

US$197m

Mar 31 2021n/an/a

US$203m

Dec 31 2020US$17mUS$296k

US$85m

Sep 30 2020n/an/a

-US$285k

Jun 30 2020n/an/a

US$2m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$250kUS$177k

-US$2m

Compensatie versus markt: De totale vergoeding ($USD 714.94K ) Carl } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.20M ).

Compensatie versus inkomsten: De vergoeding van Carl is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Carl Hansen (49 yo)

12yrs

Tenure

US$714,939

Compensatie

Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Carl Hansen
CEO, President & Chairperson12yrsUS$714.94k19.27%
$ 154.8m
Andrew Booth
Chief Financial Officer5.3yrsUS$674.56k0.096%
$ 772.4k
Veronique Lecault
COO & Director5.8yrsUS$650.59k3.25%
$ 26.1m
Tryn Stimart
Chief Legal Officer5.3yrsUS$667.69k0.00017%
$ 1.4k
Marcie Thiessen
Senior Director of Finance & Accountingno datageen gegevensgeen gegevens
Ester Falconer
Chief Technology Officer3.8yrsgeen gegevensgeen gegevens
Kathleen Reid
Head of Corporate Communicationsless than a yeargeen gegevensgeen gegevens
Graham Craig
Director of Corporate Development1.8yrsgeen gegevensgeen gegevens
Murray McCutcheon
Senior Vice President of Partnering1.8yrsgeen gegevensgeen gegevens
Neil Aubuchon
Chief Commercial Officer2.8yrsUS$5.61m0.016%
$ 131.7k
Adam Clarke
Senior Vice President of Discoveryno datageen gegevensgeen gegevens
Paul Colussi
Site Head & VP of Complex Membrane Protein Technologies1.8yrsgeen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ABCL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Carl Hansen
CEO, President & Chairperson12yrsUS$714.94k19.27%
$ 154.8m
Veronique Lecault
COO & Director6.3yrsUS$650.59k3.25%
$ 26.1m
Michael Hayden
Independent Lead Director5.2yrsUS$105.00k0.49%
$ 3.9m
John Montalbano
Independent Non-Employee Director4yrsUS$77.50k0.031%
$ 247.5k
Wen-Chaun Lo
Independent Director2.9yrsUS$55.00k0%
$ 0

5.2yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ABCL wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).